Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer

J. Blazek, P. Hosek, K. Hrabcova, M. Bratova, J. Kultan, M. Hrnciarik, M. Cernovska, P. Zemanova, J. Krejci, L. Koubkova, M. Stastny, M. Svaton

. 2023 ; 37 (5) : 2229-2236. [pub] -

Status neindexováno Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015345

BACKGROUND/AIM: The aim of this study was to investigate possible association between adverse events of nivolumab therapy and the effectiveness of treatment in patients with non-small cell lung cancer (NSCLC). Focusing on serious adverse events (i.e., those of grade ≥3), we evaluated overall survival (OS), progression-free survival (PFS), as well as objective response rate (ORR) to treatment. PATIENTS AND METHODS: We retrospectively analyzed a set of patients from the TULUNG database of NSCLC treated with nivolumab in eight oncology centers. We evaluated OS data based upon this set. To reduce possible bias, we further evaluated a subgroup of patients treated at the University Hospital in Pilsen, where the occurrence of adverse events, PFS, and ORR were independently examined by two experienced physicians. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: We observed significantly greater OS, PFS, and ORR in the group of patients experiencing adverse events upon nivolumab treatment versus in those patients without such events. Although the univariable model analyzing the data set of all patients demonstrated higher OS in patients with serious adverse events, only a nonsignificant trend was observed in the Cox multivariable model. In a subgroup of patients with PFS and ORR evaluation, we did observe significant, favorable effects for patients having had serious adverse effects. CONCLUSION: Patients experiencing severe adverse events show a tendency toward better OS, PFS, and ORR compared to patients without or having only mild adverse events with nivolumab treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015345
003      
CZ-PrNML
005      
20231020093505.0
007      
ta
008      
231010s2023 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.13324 $2 doi
035    __
$a (PubMed)37652490
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Blazek, Jiri $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic
245    10
$a Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer / $c J. Blazek, P. Hosek, K. Hrabcova, M. Bratova, J. Kultan, M. Hrnciarik, M. Cernovska, P. Zemanova, J. Krejci, L. Koubkova, M. Stastny, M. Svaton
520    9_
$a BACKGROUND/AIM: The aim of this study was to investigate possible association between adverse events of nivolumab therapy and the effectiveness of treatment in patients with non-small cell lung cancer (NSCLC). Focusing on serious adverse events (i.e., those of grade ≥3), we evaluated overall survival (OS), progression-free survival (PFS), as well as objective response rate (ORR) to treatment. PATIENTS AND METHODS: We retrospectively analyzed a set of patients from the TULUNG database of NSCLC treated with nivolumab in eight oncology centers. We evaluated OS data based upon this set. To reduce possible bias, we further evaluated a subgroup of patients treated at the University Hospital in Pilsen, where the occurrence of adverse events, PFS, and ORR were independently examined by two experienced physicians. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: We observed significantly greater OS, PFS, and ORR in the group of patients experiencing adverse events upon nivolumab treatment versus in those patients without such events. Although the univariable model analyzing the data set of all patients demonstrated higher OS in patients with serious adverse events, only a nonsignificant trend was observed in the Cox multivariable model. In a subgroup of patients with PFS and ORR evaluation, we did observe significant, favorable effects for patients having had serious adverse effects. CONCLUSION: Patients experiencing severe adverse events show a tendency toward better OS, PFS, and ORR compared to patients without or having only mild adverse events with nivolumab treatment.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hosek, Petr $u Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Hrabcova, Karolina $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Bratova, Monika $u Department of Respiratory Diseases, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kultan, Juraj $u Department of Respiratory Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Hrnciarik, Michal $u Department of Pneumology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Cernovska, Marketa $u Department of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic
700    1_
$a Zemanova, Petra $u Department of Oncology, First Faculty of Medicine in Prague, Charles University, Prague, Czech Republic
700    1_
$a Krejci, Jana $u Department of Pneumology, Third Faculty of Medicine and Bulovka University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Koubkova, Leona $u Department of Pneumology, Second Faculty of Medicine and Motol University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Stastny, Marek $u BMS Czech Republic, Prague, Czech Republic
700    1_
$a Svaton, Martin $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic; svatonm@fnplzen.cz
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 37, č. 5 (2023), s. 2229-2236
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37652490 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093459 $b ABA008
999    __
$a ok $b bmc $g 1997103 $s 1201707
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 37 $c 5 $d 2229-2236 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Možnosti archivace